Related Experiment Video

Updated: Nov 4, 2025

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

991

Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis

Taha Ahmed1, Alla Y Grigorian2, Adrian W Messerli3

  • 1Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|May 29, 2021
PubMed

Insights

Patients with liver cirrhosis (LC) face higher risks with acute coronary syndromes (ACS). Optimal medical therapy and invasive strategies improve survival but are underutilized in this complex population.

Area of Science:

  • Cardiology
  • Hepatology

Background:

  • Liver cirrhosis (LC) is increasingly prevalent in patients with acute coronary syndromes (ACS).
  • LC is associated with heightened cardiovascular morbidity and mortality, complicating ACS management.
  • Cirrhosis is an independent risk factor for adverse outcomes in ACS patients.

Purpose of the Study:

  • To review current data on managing ACS in patients with LC.
  • To provide a practical, clinically oriented approach for this patient cohort.
  • To highlight the scarcity of literature on antithrombotic safety and invasive strategies in LC patients with ACS.

Main Methods:

  • Literature review of existing data on ACS management in liver cirrhosis.
  • Analysis of challenges related to hepatic drug metabolism and function assessment.
  • Examination of current treatment underutilization in this population.

Main Results:

  • Optimal medical therapy and invasive revascularization demonstrate survival benefits in LC patients with ACS.
  • Antithrombotic drug management requires careful hepatic function assessment.
  • Definitive guidelines are lacking due to exclusion from major clinical trials.

Conclusions:

  • ACS management in liver cirrhosis requires tailored approaches due to unique complications.
  • Increased utilization of evidence-based therapies is crucial for improving outcomes.
  • Randomized clinical trials are urgently needed to refine management strategies for LC patients with ACS.

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

431

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
70
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
98
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
205
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
52
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
95
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
89